Somerville ER Sen A.

Morvan just a syndrome…!.

Lancet North Am Ed. 2017; 389: 1368View in Article Scopus (1) PubMed Abstract Full Text Full Text PDF Google ScholarIrani SR Pettingill P Kleopa KA Schiza N Waters P Mazia C et al.

Morvan syndrome: clinical and serological observations in 29 cases.

Ann Neurol. 2012; 72: 241-255View in Article Scopus (335) PubMed Crossref Google Scholarvan Sonderen A Ariño H Petit-Pedrol M Leypoldt F Körtvélyessy P Wandinger K-P et al.

The clinical spectrum of Caspr2 antibody–associated disease.

Neurology. 2016; 87: 521-528View in Article Scopus (202) PubMed Crossref Google ScholarBinks SN Klein CJ Waters P Pittock SJ Irani SR.

LGI1, CASPR2 and related antibodies: a molecular evolution of the phenotypes.

Journal of Neurology, Neurosurgery & Psychiatry. 2018; 89: 526-534View in Article Scopus (92) PubMed Crossref Google ScholarSteriade C Mirsattari SM Murray BJ Wennberg R.

Subclinical temporal EEG seizure pattern in LGI 1-antibody–mediated encephalitis.

Epilepsia. 2016; 57: e155-e160View in Article Scopus (30) PubMed Crossref Google ScholarQin X Yang H Zhu F Wang Q Shan W.

Clinical Character of CASPR2 Autoimmune Encephalitis: A Multiple Center Retrospective Study.

Front Immunol. 2021; 12View in Article Scopus (7) Crossref Google ScholarLaurencin C André-Obadia N Camdessanché J-P Mauguière F Ong E Vukusic S et al.

Peripheral small fiber dysfunction and neuropathic pain in patients with Morvan syndrome.

Neurology. 2015; 85: 2076-2078View in Article Scopus (23) PubMed Crossref Google ScholarRamanathan S Tseng M Davies AJ Uy CE Paneva S Mgbachi VC et al.

Leucine-Rich Glioma-Inactivated 1 versus Contactin-Associated Protein-like 2 antibody neuropathic pain: clinical and biological comparisons.

Ann Neurol. 2021; 90: 683-690View in Article Scopus (6) PubMed Crossref Google ScholarDawes JM Weir GA Middleton SJ Patel R Chisholm KI Pettingill P et al.

Immune or genetic-mediated disruption of CASPR2 causes pain hypersensitivity due to enhanced primary afferent excitability.

Neuron. 2018; 97 (e10): 806-822View in Article Scopus (82) PubMed Abstract Full Text Full Text PDF Google ScholarBoyko M Au KLK Casault C de Robles P Pfeffer G.

Systematic review of the clinical spectrum of CASPR2 antibody syndrome.

J Neurol. 2020; 267: 1137-1146View in Article Scopus (24) PubMed Crossref Google ScholarAbou-Zeid E Boursoulian LJ Metzer WS Gundogdu B.

Morvan syndrome: a case report and review of the literature.

Journal of clinical neuromuscular disease. 2012; 13: 214-227View in Article Scopus (43) PubMed Crossref Google ScholarPérez CA Shah EG Butler IJ.

Mercury-induced autoimmunity: report of two adolescent siblings with Morvan syndrome “plus” and review of the literature.

J Neuroimmunol. 2020; 342577197View in Article Scopus (5) Abstract Full Text Full Text PDF Google ScholarJiang C Zhang J Jia C Hong M Wang J Yang Y.

Morvan Syndrome and Diffuse Large B-Cell Lymphoma in the Central Nervous System.

Neurologist. 2020; 25: 73-77View in Article Scopus (2) PubMed Crossref Google ScholarSveinsson O Al Nimer F Piehl F

Morvan's syndrome treated successfully with rituximab and lacosamide.

BMJ Case Reports CP. 2019; 12e226832View in Article PubMed Google ScholarOng E Viaccoz A Ducray F Pérol M Cavillon G Rogemond V et al.

Dramatic improvement after rituximab in a patient with paraneoplastic treatment-refractory Morvan syndrome associated with anti-CASPR2 antibodies.

Eur J Neurol. 2013; 20: e96-e97View in Article Scopus (16) PubMed Crossref Google ScholarWeiss M.

Rituximab therapy for morvan syndrome associated with myasthenia gravis.

Muscle Nerve. 2012; 46: 139-140View in Article Scopus (5) PubMed Crossref Google ScholarSadnicka A Reilly MM Mummery C Brandner S Hirsch N Lunn MP.

Rituximab in the treatment of three coexistent neurological autoimmune diseases: chronic inflammatory demyelinating polyradiculoneuropathy, Morvan syndrome and myasthenia gravis.

Journal of Neurology, Neurosurgery & Psychiatry. 2011; 82: 230-232View in Article Scopus (30) PubMed Crossref Google ScholarDíaz-Manera J Rojas-García R Gallardo E Juárez C Martínez-Domeño A Martínez-Ramírez S et al.

Antibodies to AChR, MuSK and VGKC in a patient with myasthenia gravis and Morvan's syndrome.

Nature clinical practice Neurology. 2007; 3: 405-410View in Article Scopus (62) PubMed Crossref Google ScholarIrani SR Alexander S Waters P Kleopa KA Pettingill P Zuliani L et al.

Antibodies to Kv1 potassium channel-complex proteins leucine-rich, glioma inactivated 1 protein and contactin-associated protein-2 in limbic encephalitis, Morvan’s syndrome and acquired neuromyotonia.

Brain. 2010; 133: 2734-2748View in Article Scopus (947) PubMed Crossref Google ScholarLang B Makuch M Moloney T Dettmann I Mindorf S Probst C et al.

Intracellular and non-neuronal targets of voltage-gated potassium channel complex antibodies.

Journal of Neurology, Neurosurgery & Psychiatry. 2017; 88: 353-361View in Article Scopus (81) PubMed Crossref Google ScholarThaler FS Zimmermann L Kammermeier S Strippel C Ringelstein M Kraft A et al.

Rituximab Treatment and Long-term Outcome of Patients With Autoimmune Encephalitis: Real-world Evidence From the GENERATE Registry.

Neurology-Neuroimmunology Neuroinflammation. 2021; 8View in Article Scopus (6) Crossref Google ScholarSong J Jing S Quan C Lu J Qiao X Qiao K et al.

Isaacs syndrome with CASPR2 antibody: a series of three cases.

J Clin Neurosci. 2017; 41: 63-66View in Article Scopus (12) PubMed Abstract Full Text Full Text PDF Google ScholarAbboud H Probasco J Irani SR Ances B Benavides DR Bradshaw M et al.

Autoimmune encephalitis: proposed recommendations for symptomatic and long-term management.

Journal of Neurology, Neurosurgery & Psychiatry. 2021; View in Article Google ScholarQiao S H-k Wu L-l Liu M-l Wang R-r Zhang Han T et al.

Clinical features and long-term outcomes of anti-leucine-rich glioma-inactivated 1 encephalitis: a multi-center study.

Neuropsychiatric Disease and Treatment. 2021; 17: 203View in Article Scopus (9) PubMed Crossref Google Scholar